Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
immunotherapy |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2018 |
| gptkbp:ATCCode |
L01FF06
|
| gptkbp:brand |
gptkb:Libtayo
|
| gptkbp:developedBy |
gptkb:Sanofi
gptkb:Regeneron_Pharmaceuticals |
| https://www.w3.org/2000/01/rdf-schema#label |
cemiplimab
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
PD-1 inhibitor
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
diarrhea
fatigue rash immune-related adverse events |
| gptkbp:target |
gptkb:PD-1
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
gptkb:cutaneous_squamous_cell_carcinoma |
| gptkbp:bfsParent |
gptkb:programmed_cell_death_protein_1_(PD-1)
|
| gptkbp:bfsLayer |
6
|